Key Takeaway: Eloxx Pharmaceuticals has reported significant achievements, including the presentation of data from its proof-of-concept trial in NMAS patients at ASN Kidney Week. New analyses confirmed the production of collagen types α14 and α15 in patients treated with ELX-02. Additionally, the FDA has permitted continued dosing of subjects in the Phase 1 trial of ZKN-013.
Price reaction · baseline $0.0011 (2024-11-11 close) · clean, no other ELOX news in the window
day 0 close
0%
day 1
0%
day 3
0%
Market Sentiment Analysis
POSITIVE FACTORS
Successful presentation of trial data at ASN Kidney Week.
Confirmation of collagen production in patients post-treatment.
FDA approval for continued dosing in Phase 1 trial.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+144%
120-day peak, hindsight
Typical move
20.6%
average across 3 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Full Press Release Details
Data from Eloxx’s proof-of-concept trial in NMAS patients presented in a late-breaking presentation at ASN Kidney Week. New protein analyses confirm production of both collagen α4 and collagen α5 in patients post-treatment with ELX-02. FDA allows continued dosing of subjects in Phase 1 trial of ZKN-013.
The post Eloxx Pharmaceuticals Announces Key Corporate Accomplishments appeared first on Eloxx Pharmaceuticals .
Frequently Asked Questions
What were the key accomplishments announced by Eloxx?
Eloxx announced successful trial data presentation and FDA approval for continued dosing.
Where was the trial data presented?
The trial data was presented at ASN Kidney Week.
What types of collagen were confirmed post-treatment?
Collagen types α14 and α15 were confirmed in patients post-treatment with ELX-02.
What trial is ZKN-013 related to?
ZKN-013 is in a Phase 1 trial for which the FDA allowed continued dosing.
Biotech snapshot
Cash runway
$62M liquidity · $2M/mo burn
~37 mo
Minimal dilution risk
Catalyst track record
+144%
best trade around ELOX's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ELOX.